CTLA4 and cancer: Herein, we focus on the safety and efficacy of approved (sipuleucel-T and talimogene laherparepvec [T-VEC]) and promising cancer vaccines alone or combined with ICIs (cytotoxic T-lymphocyte-associated protein 4 [CTLA-4] and, programmed cell death 1 [PD-1] and its ligands [PD-L1]) for the treatment of several malignancies.